Not recruitingEUCTR 2006-004147-33
An Eight-Week, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Fixed Dose of SR58611A 350 mg Twice a Day in Elderly Patients with Generalized ...
This historical record does not confirm current site availability.
Historical research recordMultiple countriesAnxiety
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Austria · Finland and 1 more location
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Not recruiting
- Enrollment listed in the registry
- 270
- Sponsor
- sanofi-aventis recherche & développement
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Austria, Finland, Slovakia
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2006-004147-33
- Official title
Show the full official title
An Eight-Week, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Fixed Dose of SR58611A 350 mg Twice a Day in Elderly Patients with Generalized ...
Recruitment & locations
Not recruitingAustria · Finland · Slovakia
Registry details
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is sanofi-aventis recherche & développement.
Is this study still recruiting?
The historical registry lists this study as not recruiting.
Want to explore more studies?
Explore studiesRelated studies
AN 8 WEEK, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 3 TRIAL OF PREGABALIN (150 600 MG/DAY) IN THE ADJUNCTIVE TREATMENT OF PATIENTS WITH GENERALIZED ANXIETY DISORDER (GAD) WHO HAVE NOT OPTIMALLY RESP...
Efficacy and safety of agomelatine for 12 weeks in non-depressed out-patients with Generalised Anxiety Disorder
